Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited has announced a significant change in director Jason Carroll’s holdings, with the acquisition of 1,692,514 ordinary shares at a total value of $36,090.04. Following the on-market purchase, Carroll’s total direct interest in the company has increased to 36,145,262 ordinary shares. The transaction demonstrates a reinforcing of Carroll’s stake in the company, signaling potential insider confidence to investors.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
